Conbercept combined with laser photocoagulation in the treatment of diabetic macular edema and its influence on intraocular cytokines

Table 1 Clinical effects

Group	Number of cases	Invalid, n (%)	Valid, n (%)	Excellent, n (%)	Total effective rate (%)
Control group	65	14 (21.54)	41 (63.08)	10 (15.38)	78.46
Observation group	65	4 (6.15)	41 (63.08)	20 (30.77)	93.85
χ2 value					8.88
P value					0.04

Table 2 Comparison of best-corrected visual acuity before and after treatment

Group	Number of cases	BCVA
		Prior treatment	One month of treatment	Three months of treatment	Treatment for 6 mo
Control group	65	0.07 ± 0.02	0.22 ± 0.081	0.30 ± 0.161,2	0.49 ± 0.201,2,3
Observation group	65	0.07 ± 0.02	0.21 ± 0.061	0.44 ± 0.161,2	0.62 ± 0.221,2,3
t value		1.224	-5.221	-6.804	-4.439
P value		0.223	< 0.001	< 0.001	< 0.001

¹Indicates the intra-group comparison with that before treatment, P < 0.05.

²Indicates that compared with 1 mo after treatment, P < 0.05.

³Indicates ^aP < 0.05, in the group compared with 3 mo of treatment.

BCVA: Best-corrected visual acuity.

Table 3 Retinal thickness before and after treatment

Group	Number of cases	Retinal thickness (μm)
		Prior treatment	One month of treatment	Three months of treatment	Treatment for 6 mo
Control group	65	637.20 ± 101.96	431.12 ± 90.221	320.16 ± 88.711,2	241.92 ± 70.431,2,3
Observation group	65	638.39 ± 103.16	316.31 ± 86.721	221.43 ± 90.221,2	170.62 ± 72.341,2,3
t value		-0.492	6.216	6.535	5.863
P value		0.624	< 0.001	< 0.001	< 0.001

¹Indicates the intra-group comparison with that before treatment, P < 0.05.

²demonstrates that compared with 1 mo after treatment, P < 0.05.

³Indicates P < 0.05, in the group compared with 3 mo of treatment.

Table 4 Before and after central macular thickness treatment

Group	Number of cases	CMT (μm)
		Prior treatment	One month of treatment	Three months of treatment	Treatment for 6 mo
Control group	65	360.60 ± 41.62	307.32 ± 39.421	270.38 ± 34.671,2	236.71 ± 32.311,2,3
Observation group	65	357.63 ± 42.51	249.31 ± 36.211	221.62 ± 31.621,2	183.26 ± 33.321,2,3
t value		0.493	8.949	8.611	9.175
P value		0.623	< 0.001	< 0.001	< 0.001

¹Indicates the intra-group comparison with that before treatment, P < 0.05.

²Indicates that compared with 1 mo after treatment, P < 0.05.

³Indicates intra-group comparison with 3-mo treatment, P < 0.05.

CMT: Central macular thickness.

Table 5 Levels of vascular endothelial growth factor before and after treatment

Group	Number of cases	VEGF (ng/mL)
		Prior treatment	One month of treatment	Three months of treatment	Treatment for 6 mo
Control group	65	423.73 ± 76.35	336.73 ± 65.281	170.30 ± 41.321,2	106.32 ± 10.711,2,3
Observation group	65	424.32 ± 77.31	301.62 ± 63.781	110.32 ± 36.721,2	66.79 ± 10.211,2,3
t value		-0.151	3.512	8.707	21.818
P value		0.880	< 0.001	< 0.001	< 0.001

¹Indicates the intra-group comparison with that before treatment, P < 0.05.

²Indicates that compared with 1 month after treatment, P < 0.05.

³Indicates intra-group comparison with 3-mo treatment, P < 0.05.

VEGF: Vascular endothelial growth factor.

Table 6 Interleukin-6 levels before and after treatment

Group	Number of cases	IL-6 (ng/mL)
		Prior treatment	One month of treatment	Three months of treatment	Treatment for 6 mo
Control group	65	76.31 ± 11.76	66.31 ± 11.761	52.34 ± 8.711,2	42.91 ± 5.931,2,3
Observation group	65	75.24 ± 12.03	60.12 ± 8.031	45.71 ± 7.621,2	34.73 ± 5.631,2,3
t value		0.196	4.476	3.981	8.309
P value		0.845	< 0.001	< 0.001	< 0.001

¹Indicates the intra-group comparison with that before treatment, P < 0.05.

²Indicates that compared with 1 mo after treatment, P < 0.05.

³Indicates intra-group comparison with 3-mo treatment, P < 0.05.

IL-6: Interleukin-6.

Table 7 Levels of soluble intercellular adhesion molecule-1 before and after treatment

Group	Number of cases	sICAM-1 (ng/mL)
		Prior treatment	One month of treatment	Three months of treatment	Treatment for 6 mo
Control group	65	373.37 ± 83.12	313.71 ± 54.621	236.42 ± 37.911,2	205.71 ± 20.311,2,3
Observation group	65	376.39 ± 83.83	280.18 ± 54.621	200.73 ± 37.911,2	180.31 ± 20.721,2,3
t value		-0.043	3.850	5.325	7.120
P value		0.966	< 0.001	< 0.001	< 0.001

¹Indicates the intra-group comparison with that before treatment, P < 0.05.

²Indicates that compared with 1 mo after treatment, P < 0.05.

³Indicates intra-group comparison with 3-mo treatment, ^aP < 0.05.

sICAM-1: Soluble intercellular adhesion molecule-1.

Table 8 Levels before and after serum basic fibroblast growth factor treatment

Group	Number of cases	BFGF (g/L)
		Prior treatment	One month of treatment	Three months of treatment	Treatment for 6 mo
Control group	65	52.16 ± 8.17	49.31 ± 7.281	40.21 ± 6.221,2	32.41 ± 3.211,2,3
Observation group	65	53.07 ± 8.02	44.12 ± 7.161	33.34 ± 5.981,2	23.62 ± 3.161,2,3
t value		-0.201	3.675	6.601	11.661
P value		0.841	< 0.001	< 0.001	< 0.001

¹Indicates the intra-group comparison with that before treatment, P < 0.05.

²Indicates that compared with 1 mo after treatment, P < 0.05.

³Indicates intra-group comparison with 3-mo treatment, P < 0.05.

BFGF: Basic fibroblast growth factor.